Jason Diamond

The topic of this article may not meet Wikipedia's notability guideline for biographies. Please help demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Jason Diamond" – news · newspapers · books · scholar · JSTOR (November 2016) (Learn how and when to remove this message)

Jason B. Diamond, M.D., F.A.C.S. (born December 21, 1970, in Glen Ridge, New Jersey) is an American facial plastic surgeon(ENT) and television personality.

Early life

Diamond attended the University of Rochester School of Medicine.

Career

Diamond has appeared on the E! Network show, Dr. 90210. Diamond has been featured in various print media, such as People Magazine, Vogue, Elle, and Marie Claire.^{[volume and issue needed]}

In 2010, Diamond got his license to perform surgery in Dubai.

He is in private practice specializing in facial plastic and reconstructive surgery and has offices in Beverly Hills, New York City, Dubai, and Moscow.

Published works

• Diamond, Jason; Gerut, Zachary E; Shire, James R.; Nguyen, Davis B.; Chen, Achih H.; Desmond, Julian C.; Silvati-Fidell, Laura; Abrams, Steve Zvi. "Exploratory, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Adjuvant Fibrin Sealant VH S/D 4 S-Apr (ARTISS) in Patients Undergoing Rhytidectomy." Aesthetic Surgery Journal. 33.3 (2013): 323-333. Print.
• Diamond, J; Skaggs, J; Manaligod, JM (2002). "Free-radical damage: a possible mechanism of laryngeal aging". Ear Nose Throat J. 81: 531–3. PMID 12199170.
• "A Single Dose, Open Label Three Way Crossover, Randomized Pilot Bioavailability Study of Midozolam. Comparing Intranasal Administration to Intramuscular Administration in Healthy Human Volunteers." University of Kentucky Medical Center Protocol Mz0001.
• "A single dose, Open Label, Randomized Three Way Crossover, Bioavailability Study of 1.0 mg and 2.0 Intranasal Butorphanol Tartrate Compared to 2.0 mg. Intravenous Botorphanol Tartrate In Healthy Human Volunteers." University of Kentucky Chandler Medical Center Protocol BT002.
• "A single Dose, Randomized Two Period Crossover Pharmacokinetic Study of 2.0 mg Intranasal Hydromorphone Hydrochloride In Healthy Human Volunteers Using 10 mg/ml and 20 mg/ml Formulations. University of Kentucky Medical Center Protocol HM-114.